Phase 1/2 Trial of Pembrolizumab and Concurrent Chemoradiation Therapy for Limited-Stage SCLC
Open accessAbstract
Introduction Few advancements in treating limited-stage SCLC (LS-SCLC) have been made in decades. We report here a phase 1/2 trial of concurrent chemoradiotherapy (CRT) and pembrolizumab.Methods This single-center, open-label phase 1/2 study recruited adults with LS-SCLC or other neuroendocrine tumors and good performance status (Eastern Cooperative Oncology Group ≤ 2). The primary end point was safety, as assessed by dose-limiting toxicities. Concurrent CRT consisted of etoposide and a platin with 45 Gy radiotherapy (30 twice daily). Prophylactic cranial irradiation (25 Gy, 10 fractions) was given at the physician's discretion. Pembrolizumab was started concurrently with CRT and continued for up to 16 cycles. The phase 1 portion consisted of a 3 + 3 design. Toxicity was assessed with Common Terminology Criteria for Adverse Events version 4.0. Secondary outcomes were progression-free survival, overall survival, and tumor response as measured by the immune-related response criteria.Results A total of 45 patients were screened, and 40 were enrolled. All completed radiation therapy and received greater than or equal to one cycle of pembrolizumab. A total of 27 (61%) received percutaneous coronary intervention. One dose-limiting toxicity was observed in the phase 1 portion. There were no grade 5 toxicities, but there were three grade 4 events (two neutropenia, one respiratory failure). Pneumonitis rate was 15% (three grade 2 and three grade 3). All 17 esophagitis events (42.5%) were grades 1 to 2. At median follow-up time of 23.1 months, the median progression-free survival time was 19.7 months (95% confidence interval: 8.8‒30.5) and the median overall survival time was 39.5 months (95% confidence interval: 8.0‒71.0).Conclusion Concurrent CRT and pembrolizumab for LS-SCLC was well tolerated and yielded favorable outcomes, providing a basis for randomized studies.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
α-PD-1/PD-L1 plus chemoradiotherapy was tolerable in advanced NSCLC, HNSCC, and SCLC patients, with promising clinical outcomes, in phase 1/2 studies.
“Moreover, the results of some phase 1/2 studies (NCT02621398, NCT02434081, NCT02586207, NCT02383212, and NCT02402920) showed that α-PD-1/PD-L1 plus chemoradiotherapy was tolerable in advanced NSCLC, head and neck squamous cell carcinoma (HNSCC), and SCLC patients, with promising clinical outcomes [78–82].”
From Combination strategies with PD-1/PD-L1 blockade: current advances and future directions (2022) · cites this paper as [82]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989 · see citing works
Siegel, R. L., Miller, K. D., & Jemal, A. (2018) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21442 · Cited by 16,632 · see citing works
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Reck, M., Rodríguez-Abreu, D., Robinson, A. G., Hui, R., Csőszi, T., Fülöp, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1606774 · Cited by 10,089 · see citing works
Pembrolizumab versus Ipilimumab in Advanced Melanoma
Robert, C., Schachter, J., Long, G. V., Arance, A., Grob, J. J., Mortier, L., Daud, A., Carlino, M. S., McNeil, C., Lotem, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1503093 · Cited by 5,887 · see citing works
Durvalumab after chemoradiotherapy in stage III non–small-cell lung cancer
Antonia, S. J., Villegas, A., Daniel, D., Vicente, D., Murakami, S., Hui, R., Yokoi, T., Chiappori, A., Lee, K. H., de Wit, M., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1709937 · Cited by 4,593 · see citing works
Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden
Chalmers, Z. R., Connelly, C. F., Fabrizio, D., Gay, L., Ali, S. M., Ennis, R., Schrock, A., Campbell, B., Shlien, A., Chmielecki, J., et al. (2017) · Genome Medicine · doi:10.1186/s13073-017-0424-2 · Cited by 3,519 · see citing works
Wolchok, J. D., Hoos, A., O'Day, S. J., Weber, J. S., Hamid, O., Lebbé, C., Maio, M., Binder, M., Bohnsack, O., Nichol, G. M., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1624 · Cited by 3,214 · see citing works
Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC
Antonia, S. J., Villegas, A., Daniel, D., Vicente, D., Murakami, S., Hui, R., Kurata, T., Chiappori, A., Lee, K. H., de Wit, M., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1809697 · Cited by 2,798 · see citing works
Prophylactic Cranial Irradiation for Patients with Small-Cell Lung Cancer in Complete Remission
Auperin, A., Arriagada, R., Pignon, J., Pechoux, C. L., Gregor, A., Stephens, R. J., Kristjansen, P. E. G., Johnson, B. E., Ueoka, H., Wagner, H., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199908123410703 · Cited by 1,716 · see citing works
Turrisi, A. T., Kim, K., Blum, R. H., Sause, W. T., Livingston, R. B., Komaki, R. U., Wagner, H., Aisner, S. C., & Johnson, D. H. (1999) · New England Journal of Medicine · doi:10.1056/nejm199901283400403 · Cited by 1,507 · see citing works
A Meta-Analysis of Thoracic Radiotherapy for Small-Cell Lung Cancer
Pignon, J., Arriagada, R., Ihde, D. C., Johnson, D. H., Perry, M. C., Souhami, R. L., Brodin, O., Joss, R., Kies, M. S., Lebeau, B., et al. (1992) · New England Journal of Medicine · doi:10.1056/nejm199212033272302 · Cited by 1,328 · see citing works
van Meerbeeck, J. P., Fennell, D. A., & Ruysscher, D. D. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60165-7 · Cited by 1,239 · see citing works
Warde, P. R., & Payne, D. G. (1992) · Journal of Clinical Oncology · doi:10.1200/jco.1992.10.6.890 · Cited by 820 · see citing works
Incidence of Programmed Cell Death 1 Inhibitor–Related Pneumonitis in Patients With Advanced Cancer
Nishino, M., Giobbie‐Hurder, A., Hatabu, H., Ramaiya, N. H., & Hodi, F. S. (2016) · JAMA Oncology · doi:10.1001/jamaoncol.2016.2453 · Cited by 763 · see citing works
Murray, N., Coy, P., Pater, J. L., Hodson, I., Arnold, A., Zee, B. C.-Y., Payne, D. G., Kostashuk, E. C., Evans, W. K., & Dixon, P. (1993) · Journal of Clinical Oncology · doi:10.1200/jco.1993.11.2.336 · Cited by 719 · see citing works
Takada, M., Fukuoka, M., Kawahara, M., Sugiura, T., Yokoyama, A., Yokota, S., Nishiwaki, Y., Watanabe, K., Noda, K., Tamura, T., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.12.071 · Cited by 705 · see citing works
Novel cancer immunotherapy agents with survival benefit: recent successes and next steps
Sharma, P., Wagner, K., Wolchok, J. D., & Allison, J. P. (2011) · Nature reviews. Cancer · doi:10.1038/nrc3153 · Cited by 639 · see citing works
Finn, C. F., Snee, M., Ashcroft, L., Appel, W., Barlési, F., Bhatnagar, A., Bezjak, A., Cardenal, F., Fournel, P., Harden, S., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30318-2 · Cited by 595 · see citing works
Takahashi, T., Yamanaka, T., Seto, T., Harada, H., Nokihara, H., Saka, H., Nishio, M., Kaneda, H., Takayama, K., Ishimoto, O., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30230-9 · Cited by 551 · see citing works
Ott, P. A., Élez, E., Hiret, S., Kim, D., Morosky, A., Saraf, S., Piperdi, B., & Mehnert, J. M. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.72.5069 · Cited by 520 · see citing works
Chemotherapy with or without Radiation Therapy in Limited Small-Cell Carcinoma of the Lung
Perry, M. C., Eaton, W. L., PROPERT, K. J., Ware, J. H., Zimmer, B., Chahinian, A. P., Skarin, A. T., Carey, R. W., Kreisman, H., Faulkner, C. S., et al. (1987) · New England Journal of Medicine · doi:10.1056/nejm198704093161504 · Cited by 479 · see citing works
Acquired resistance to immunotherapy and future challenges
Restifo, N. P., Smyth, M. J., & Snyder, A. (2016) · Nature reviews. Cancer · doi:10.1038/nrc.2016.2 · Cited by 463 · see citing works
In situ vaccination by radiotherapy to improve responses to anti-CTLA-4 treatment
Vanpouille‐Box, C., Pilones, K. A., Wennerberg, E., Formenti, S. C., & Demaria, S. (2015) · Vaccine · doi:10.1016/j.vaccine.2015.05.105 · Cited by 176 · see citing works
Specific organ metastases and survival in small cell lung cancer
Nakazawa, K., Kurishima, K., Tamura, T., Kagohashi, K., Ishikawa, H., Satoh, H., & Hizawa, N. (2012) · Oncology Letters · doi:10.3892/ol.2012.792 · Cited by 173 · see citing works
Jabbour, S. K., Berman, A. T., Decker, R. H., Lin, Y., Feigenberg, S. J., Gettinger, S. N., Aggarwal, C., Langer, C. J., Simone, C. B., Bradley, J. D., et al. (2020) · JAMA Oncology · doi:10.1001/jamaoncol.2019.6731 · Cited by 125 · see citing works
Endris, V., Buchhalter, I., Allgäuer, M., Rempel, E., Lier, A., Volckmar, A., Kirchner, M., von Winterfeld, M., Leichsenring, J., Neumann, O., et al. (2018) · International Journal of Cancer · doi:10.1002/ijc.32002 · Cited by 106 · see citing works
Johnson, D. H., Bass, D., Einhorn, L. H., Crawford, J., Pérez, C. A., Bartolucci, A., Omura, G., & Greco, F. A. (1993) · Journal of Clinical Oncology · doi:10.1200/jco.1993.11.7.1223 · Cited by 66 · see citing works
Durm, G. A., Althouse, S. K., Sadiq, A. A., Jalal, S. I., Jabbour, S. K., Zon, R. T., Kloecker, G. H., Fisher, W. B., Reckamp, K. L., Kio, E. A., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.36.15_suppl.8500 · Cited by 51 · see citing works
Aisner, J., Goutsou, M., Maurer, L. H., Cooper, R. G., Chahinian, P. A., Carey, R. W., Skarin, A. T., Slawson, R. G., Perry, M. C., & Green, M. R. (1992) · Journal of Clinical Oncology · doi:10.1200/jco.1992.10.8.1230 · Cited by 41 · see citing works
Overview of Ongoing Clinical Trials Investigating Combined Radiotherapy and Immunotherapy
Cushman, T. R., Caetano, M. S., Welsh, J. W., & Verma, V. (2018) · Immunotherapy · doi:10.2217/imt-2018-0019 · Cited by 33 · see citing works
Self-citation
Flagged first, then by citations
1 of the 31 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Combination strategies with PD-1/PD-L1 blockade: current advances and future directions
Yi, M., Zheng, X., Niu, M., Zhu, S., Ge, H., & Wu, K. (2022) · Molecular Cancer · doi:10.1186/s12943-021-01489-2 · Cited by 1,445 · see citing works
Radiotherapy combined with immunotherapy: the dawn of cancer treatment
Zhang, Z., Liu, X., Chen, D., & Yu, J. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01102-y · Cited by 695 · see citing works
Self-citationMegyesfalvi, Z., Gay, C. M., Popper, H., Pirker, R., Ostoros, G., Heeke, S., Lang, C., Höetzenecker, K., Solta, A., Boettiger, K., et al. (2023) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21785 · Cited by 390 · see citing works
Self-citationSmall cell lung cancer: a slightly less orphan disease after immunotherapy
Remón, J., Aldea, M. D., Besse, B., Planchard, D., Reck, M., Giaccone, G., & Soria, J. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2021.02.025 · Cited by 102 · see citing works
Park, S., Oh, D., Choi, Y., Ah, S., Kim, K., Ahn, M., & Sun, J. (2022) · Cancer · doi:10.1002/cncr.34176 · Cited by 74 · see citing works
Pakkala, S., Higgins, K. A., Chen, Z., Sica, G., Steuer, C. E., Zhang, C., Zhang, G., Wang, S., Hossain, M. S., Nazha, B., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001302 · Cited by 68 · see citing works
Cai, L., Chen, A., & Tang, D. (2024) · Immunology · doi:10.1111/imm.13785 · Cited by 71 · see citing works
Radiation therapy for extensive-stage small-cell lung cancer in the era of immunotherapy
Tian, Y., Ma, J., Jing, X., Zhai, X., Li, Y., Guo, Z., Yu, J., & Zhu, H. (2022) · Cancer Letters · doi:10.1016/j.canlet.2022.215719 · Cited by 48 · see citing works
Durvalumab with chemoradiotherapy for limited-stage small-cell lung cancer
Park, S., Noh, J. M., Choi, Y., Ah, S., Kim, K., Jung, H. A., Lee, S., Ahn, J. S., Ahn, M., & Sun, J. (2022) · European Journal of Cancer · doi:10.1016/j.ejca.2022.03.034 · Cited by 46 · see citing works
Zhang, Z., Zhang, C., Luo, Y., Wu, P. S., Zhang, G., Zeng, Q., Wang, L., Yang, Z., Xue, L., Zheng, B. J., et al. (2021) · BMC Medicine · doi:10.1186/s12916-021-02148-5 · Cited by 44 · see citing works
Comparison of Carboplatin With Cisplatin in Small Cell Lung Cancer in US Veterans
Azar, I. H., Yazdanpanah, O., Jang, H., Austin, A., Kim, S., Chi, J., Alkassis, S., Saha, B. K., Chopra, A., Neu, K., et al. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.37699 · Cited by 40 · see citing works
Kang, K., Wu, Y., Yao, Z., & Lü, Y. (2023) · Cancer Letters · doi:10.1016/j.canlet.2023.216239 · Cited by 38 · see citing works
Elegbede, A. A., Gibson, A. J. W., Fung, A. S., Cheung, W. Y., Dean, M. L., Bebb, D. G., & Pabani, A. (2021) · JTO Clinical and Research Reports · doi:10.1016/j.jtocrr.2021.100249 · Cited by 36 · see citing works
Current and future therapies for small cell lung carcinoma
Zhai, X., Zhang, Z., Chen, Y., Wu, Y., Zhen, C., Liu, Y., Lin, Y., & Chen, C. (2025) · Journal of Hematology & Oncology · doi:10.1186/s13045-025-01690-6 · Cited by 35 · see citing works
de Ruiter, B.-M., van Hattum, J. W., Lipman, D., de Reijke, T. M., van Moorselaar, R. J. A., van Gennep, E. J., Piet, A. H. M., Donker, M., van der Hulle, T., Voortman, J., et al. (2022) · European Urology · doi:10.1016/j.eururo.2022.07.009 · Cited by 31 · see citing works
Global research landscape and trends of lung cancer immunotherapy: A bibliometric analysis
Liu, Y., Xu, C., Han, X., Cheng, X., Jiang, S., Lin, Y., Zhang, Z., Lu, L., Qu, B., Chen, Y., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1032747 · Cited by 26 · see citing works
Chen, Y., Wang, Y., Ren, F., Huang, Z., Tan, B., Zhao, Z., Yu, X., Dong, P., Yu, J., & Meng, X. (2022) · Respiratory Research · doi:10.1186/s12931-022-02196-2 · Cited by 24 · see citing works
Qi, C., Li, W., Li, H., Wen, F., Zhou, L., Sun, X., & Yu, H. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.833478 · Cited by 23 · see citing works
Mechanistic rationales for combining immunotherapy with radiotherapy
Chi, A., & Nguyen, N. P. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1125905 · Cited by 24 · see citing works
Bai, M., Wang, W., Gao, X., Wu, L., Jin, P., Wu, H., Yu, J., & Meng, X. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.832419 · Cited by 21 · see citing works
Sun, A. Y., Abdulkarim, B., Blais, N., Greenland, J., Louie, A. V., Melosky, B. L., Schellenberg, D. D., Snow, S. L., & Liu, G. (2023) · Lung Cancer · doi:10.1016/j.lungcan.2023.03.002 · Cited by 21 · see citing works
Li, Y., Wang, J., Jing, X., Sun, Y., Tang, X., Guo, J., Zhang, Y., & Zhu, H. (2023) · Discover Oncology · doi:10.1007/s12672-023-00666-7 · Cited by 21 · see citing works
Small cell lung cancer: emerging subtypes, signaling pathways, and therapeutic vulnerabilities
Zhang, J., Zeng, X., Guo, Q., Sheng, Z., Chen, Y., Wan, S., Zhang, L., & Zhang, P. (2024) · Experimental Hematology and Oncology · doi:10.1186/s40164-024-00548-w · Cited by 19 · see citing works
Self-citationZhang, X., Ge, N., Xiang, Z.-J., & Liu, T. (2022) · Cancer Cell International · doi:10.1186/s12935-022-02760-2 · Cited by 19 · see citing works
Front Line Applications and Future Directions of Immunotherapy in Small-Cell Lung Cancer
Wong, S. K., & Iams, W. T. (2021) · Cancers · doi:10.3390/cancers13030506 · Cited by 19 · see citing works
A Promising Treatment Strategy for Lung Cancer: A Combination of Radiotherapy and Immunotherapy
Miyasaka, Y., Sato, H., Okano, N., Kubo, N., Kawamura, H., & Ohno, T. (2021) · Cancers · doi:10.3390/cancers14010203 · Cited by 19 · see citing works
Rimner, A., Lai, W.-C. V., Califano, R., Jabbour, S. K., Rudin, C. M., Finn, C. F., Cho, B. C., Kato, T., Yu, J., Chafin, W., et al. (2022) · Clinical Lung Cancer · doi:10.1016/j.cllc.2022.04.005 · Cited by 18 · see citing works
Self-citationHypofractionated radiotherapy with immunochemotherapy for extensive-stage small-cell lung cancer
Liu, C., Zeng, L., Deng, C., Jiang, W., Wang, Y., Zhou, Y., Liu, L., Wang, S., Zhou, C., Qiu, Z., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1175960 · Cited by 16 · see citing works
Mi, S., Liang, N., Zhang, Y., Zhang, Y., Wang, F., Qiao, L., Chen, F., Hu, P., & Zhang, J. (2023) · Clinical Lung Cancer · doi:10.1016/j.cllc.2023.08.008 · Cited by 15 · see citing works
Self-citationImmune Checkpoint Inhibitors and Chemoradiation for Limited-Stage Small Cell Lung Cancer
Schlick, B. D., Shields, M. D., Marin-Acevedo, J. A., Patel, I., & Pellini, B. (2022) · Current Treatment Options in Oncology · doi:10.1007/s11864-022-00989-7 · Cited by 15 · see citing works
Cao, Z., Deng, K., Jiang, J., Tian, K., & Wang, B. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.117727 · Cited by 14 · see citing works
Research landscape and trends of lung cancer radiotherapy: A bibliometric analysis
Liu, Y., Jiang, S., Lin, Y., Yu, H., Yu, L., & Zhang, X. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1066557 · Cited by 13 · see citing works
Wu, B., Zhao, S., Zhang, J., Liu, Y., Bai, J., Wang, G., Wang, Y., Jiang, H., Hu, Y., Ouyang, W., et al. (2024) · Inflammation · doi:10.1007/s10753-024-02056-9 · Cited by 12 · see citing works
Self-citationRadioimmunotherapy: a game-changer for advanced non-small cell lung cancer
Xue, H., Chen, Y., & Zhou, Y. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1522508 · Cited by 12 · see citing works
Saxena, A. (2023) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2023.02.004 · Cited by 12 · see citing works
Liu, J.-C., Wang, L., Shu, W., Zhang, L., Wang, Y., Lv, W., Zhu, L., & Hu, J. (2022) · Journal of Thoracic Disease · doi:10.21037/jtd-22-1287 · Cited by 11 · see citing works
Impact of thoracic radiotherapy on first‐line treatment outcomes in ES ‐ SCLC patients
Mu, X., Zhou, Y., Liu, Q., Wang, J., Xu, F., Luo, F., Wang, K., Lu, L., Tian, P., Li, Y., et al. (2024) · Cancer Medicine · doi:10.1002/cam4.70175 · Cited by 10 · see citing works
Progress in radiotherapy for small‐cell lung cancer
Yang, F., & Zhao, H. (2023) · Precision Radiation Oncology · doi:10.1002/pro6.1205 · Cited by 10 · see citing works
Radiotherapy plus immune checkpoint inhibitor in prostate cancer
Li, T., Qian, X., Liu, J., Xue, F., Luo, J., Yao, G., Yan, J., Liu, X., Xiao, B., & Li, J. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1210673 · Cited by 10 · see citing works
Liu, Q., Zhang, Y., Liu, M., Xu, R., Yi, F., Wei, Y., Zhu, S., & Zhang, W. (2021) · World Journal of Surgical Oncology · doi:10.1186/s12957-021-02410-3 · Cited by 9 · see citing works
Xie, J., Xu, K., Cai, Z., Chen, M., Jiang, Y., Ye, J., Lin, X., Lv, T., & Zhan, P. (2024) · Translational Lung Cancer Research · doi:10.21037/tlcr-24-24 · Cited by 9 · see citing works
Immunotherapy for small cell lung cancer: the current state and future trajectories
Qiang, M., Liu, H., Yang, L., Wang, H., & Guo, R. (2024) · Discover Oncology · doi:10.1007/s12672-024-01119-5 · Cited by 9 · see citing works
Li, Y., Jiang, Y., Pan, L., Yao, J., Liang, S., Du, Y., Wang, D., Liu, H., Zhang, F., Wang, Q., et al. (2024) · Thoracic Cancer · doi:10.1111/1759-7714.15471 · Cited by 9 · see citing works
Yerolatsite, M., Torounidou, N., Amylidi, A.-L., Rapti, I.-C., Zarkavelis, G., Kampletsas, E. O., & Voulgari, P. V. (2025) · Biomedicines · doi:10.3390/biomedicines13040946 · Cited by 8 · see citing works
Johnson, R. L., Ganesan, S., Thangavelu, A., Theophilou, G., Jong, D. D., Hutson, R., Nugent, D., Broadhead, T., Laios, A., Cummings, M., et al. (2023) · Cancers · doi:10.3390/cancers15184632 · Cited by 8 · see citing works
Treatment of small cell lung cancer: recent advances
Chu, X., Han, C., & Su, C. (2021) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000804 · Cited by 8 · see citing works
Pre-existing intratumoral stem-like CD8+ T cells drive radiotherapy-induced tumor immunity
Köksal, H., Herbst, M., Perreira, P., Nater, M., Regli, N., Boudjeniba, C., Borgoni, N. E., Cecconi, V., & van den Broek, M. F. (2025) · Cell Reports · doi:10.1016/j.celrep.2025.115566 · Cited by 7 · see citing works
What Is New in Small Cell Lung Cancer
Matera, R. M., & Chiang, A. C. (2023) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2023.02.010 · Cited by 7 · see citing works
Seo, B. M., Choi, J., Chang, B., Kim, B., Park, T. S., Lee, H. J., Moon, J., Kim, S., Kim, T., Yoo, S.-J., et al. (2024) · Scientific Reports · doi:10.1038/s41598-024-61145-9 · Cited by 6 · see citing works
Zhu, L., Liu, J.-C., Huang, X., & Hu, J. (2025) · BMC Cancer · doi:10.1186/s12885-024-13405-0 · Cited by 6 · see citing works
Big Decisions on Small Cell Lung Cancer: A Focus on Clinical Care Updates and Patient Perspectives
Xiao, W., & Chiang, A. C. (2024) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_432520 · Cited by 6 · see citing works
CAR-T cell therapy: Challenge and opportunity for effective treatment of small cell lung cancer
Yin, L., Sun, P. B., Guo, S., Shuai, P., & Zhang, J. (2024) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2024.189228 · Cited by 6 · see citing works
Self-citationSun, F., Zhang, L., Sun, L., Wang, D., Song, N., Duan, L., Bian, D., Hu, J., Yan, Y., Yang, J., et al. (2025) · Cell Discovery · doi:10.1038/s41421-025-00838-5 · Cited by 5 · see citing works
How to Improve SBRT Outcomes in NSCLC: From Pre-Clinical Modeling to Successful Clinical Translation
Milić, M., Mondini, M., & Deutsch, É. (2022) · Cancers · doi:10.3390/cancers14071705 · Cited by 5 · see citing works
Yamani, N., Ahmed, A. B., Ruiz, G. S., Zubair, A., Arif, F., & Mookadam, F. (2024) · Cardio-Oncology · doi:10.1186/s40959-024-00229-x · Cited by 5 · see citing works
Hypofractionated vs. standard radiotherapy for locally advanced limited-stage small cell lung cancer
Saeed, N. A., Jin, L., Sasse, A. W., Amini, A., Verma, V., Lester-Coll, N. H., Chen, P., Decker, R. H., & Park, H. S.-M. (2022) · Journal of Thoracic Disease · doi:10.21037/jtd-21-1566 · Cited by 5 · see citing works
Self-citationBian, D., Jiang, S., Xiong, Y., Qi, M., Wu, J., Addeo, A., Yamauchi, Y., Manapov, F., Dempke, W. C. M., Vannucci, J., et al. (2022) · Translational Lung Cancer Research · doi:10.21037/tlcr-22-545 · Cited by 5 · see citing works
Zhan, T.-Y., Zhang, T., Wang, W., Deng, L., Zhai, Y., Yan, W., Wang, X., Wang, J., Liu, W., Li, M., et al. (2025) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2025.09.058 · Cited by 4 · see citing works
Self-citationZhao, S., Chen, K., Shi, X., Sun, J., Fang, W., Huang, Y., & Zhang, L. (2023) · Clinical Lung Cancer · doi:10.1016/j.cllc.2023.06.009 · Cited by 4 · see citing works
Chen, L., Kong, Y., Tong, F., Zhang, R., Ding, P., Zhang, S., Wang, Y., Zhou, R., Pu, X., Chen, B., et al. (2024) · Chinese Medical Journal · doi:10.1097/cm9.0000000000003283 · Cited by 4 · see citing works
Integration of ımmunotherapy in limited-stage small cell lung cancer: a review of the literature
Güren, A. K., Demircan, N. C., Sarı, M., & Köstek, O. (2026) · Current Medical Research and Opinion · doi:10.1080/03007995.2026.2629092 · Cited by 3 · see citing works
Kuang, Y., Singh, R., Nevo, A., Deitz, A. C., Pietanza, M. C., Liu, A., Uyei, J., & Zu, K. (2022) · Clinical Lung Cancer · doi:10.1016/j.cllc.2022.09.008 · Cited by 3 · see citing works
Xu, J., Yang, Y., Chen, T., Liu, D., Yuan, Y., & Xu, L. (2025) · Thoracic Cancer · doi:10.1111/1759-7714.70112 · Cited by 3 · see citing works
Zhang, J., Zhong, X., Wang, S., & Wang, L. (2025) · Current Oncology Reports · doi:10.1007/s11912-025-01716-9 · Cited by 2 · see citing works
Self-citationSong, C., Zhao, X., Li, S., Guo, X., Zhang, X., Wang, X., Li, Y., Yan, K., 苏景伟, Xu, J., et al. (2026) · Cancer · doi:10.1002/cncr.70351 · Cited by 2 · see citing works
Limited-Stage Small-Cell Lung Cancer: Current Progress and the Next Frontier
Toh, T. S., & Lok, B. H. (2021) · Radiation · doi:10.3390/radiation1040026 · Cited by 2 · see citing works
Yu, T., Hu, X., Liufu, W. J., Niu, S., Lian, H., Ma, H., Wang, J., Bao, Y., Chen, M., & Peng, F. (2024) · Cancer Medicine · doi:10.1002/cam4.7215 · Cited by 2 · see citing works
Shao, L., Dong, Y., Jiang, M., Song, H., Qi, Y., Guo, L., Tian, J., & Wei, S. (2025) · Oncology Letters · doi:10.3892/ol.2025.14870 · Cited by 2 · see citing works
Evolving Field of Immunotherapy: Pioneering New Paths in Small-Cell Lung Cancer
Hazim, A. Z., Leventakos, K., & Ernani, V. (2025) · JCO Oncology Practice · doi:10.1200/op-24-00862 · Cited by 2 · see citing works
Saalfeld, F. C., & Wermke, M. (2024) · Die Onkologie · doi:10.1007/s00761-024-01566-3 · Cited by 2 · see citing works
Yu, L., Yu, X., Ma, C., Zhang, X., & Cui, R. (2025) · PLoS ONE · doi:10.1371/journal.pone.0337459 · Cited by 1 · see citing works
Ebzee, R. A., Abubeker, I. Y., Aboughalia, A. T., & Danjuma, M. I. (2026) · Pharmaceuticals · doi:10.3390/ph19020219 · Cited by 1 · see citing works
Overcoming Immunotherapy Resistance in Small-Cell Lung Cancer
Canale, M., Suzzi, F., Verlicchi, A., Citarella, F., Delmonte, A., & Ulivi, P. (2026) · Biology · doi:10.3390/biology15040356 · Cited by 1 · see citing works
Zhao, Q., Li, Y., Zhang, H., Han, M. D., Kan, Y., Sun, H., Liu, C., Wang, L., Han, X., Hua, Y., et al. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-026-02668-7 · Cited by 1 · see citing works
Zhou, X. Y., Jiang, Z., Ren, Y., Zhou, Y., Deng, L., Liu, Z., Sun, S., Zhang, J., Liu, W. T., Yang, Y., et al. (2026) · Med · doi:10.1016/j.medj.2026.101180 · Cited by 1 · see citing works
Self-citation[Clinical Progress in the Immunotherapy of Small Cell Lung Cancer].
Wang, W., Zhang, J., & Li, S. (2022) · PubMed Central · doi:10.3779/j.issn.1009-3419.2022.102.15 · Cited by 1 · see citing works
Self-citationYao, N., Qin, Z. S., Ma, J., Lu, J., Sun, K., Zhang, Y., Qu, W., Cui, L., Yuan, S., Jiang, A., et al. (2022) · Journal of Chemotherapy · doi:10.1080/1120009x.2022.2125750 · Cited by 1 · see citing works
Toxicity When Combining Immunotherapy and Radiotherapy
Leaman-Alcibar, O., López‐Campos, F., Aller, J., Calín-Lorca, A., Zatarain‐Nicolás, E., Bande, M. F., & Navarro-Martín, A. (2023) · Springer eBooks · doi:10.1007/978-3-030-80962-1_339-1 · Cited by 1 · see citing works
Guo, Y. X., An, Q., Chen, L. L., Li, T. Y., Chen, D., Liang, J., Wang, L., & Jiang, W. (2023) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2023.06.695 · Cited by 1 · see citing works
Self-citationJia, J., Trassl, L., Kong, F., Deng, B., Liu, R., Sun, Z., Lan, X., Yildirim, A. Ö., Stathopoulos, G. T., Fernandez, I. E., et al. (2024) · Translational Oncology · doi:10.1016/j.tranon.2024.102070 · Cited by 1 · see citing works
Immuno-combined treatment versus radio-combined treatment in limited-stage small-cell lung cancer
Li, T., Li, X., Hu, M., Zhang, M., Wang, Y., Zhang, K., Wang, Q., Zhang, T., & Li, B. (2024) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359241307191 · Cited by 1 · see citing works
Feng, J., Wang, Y., Yao, W., Luo, J., & Yu, K. (2021) · Annals of Translational Medicine · doi:10.21037/atm-21-3353 · Cited by 1 · see citing works
Expanding the Role of Immunotherapy to Limited-Stage SCLC
Punekar, S. R., & Shum, E. (2020) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2020.09.021
Strahlentherapie des kleinzelligen Lungenkarzinoms
Gkika, E., Nestle, U., & Grosu, A. (2021) · Der Onkologe · doi:10.1007/s00761-021-00955-2
红, 艳. (2022) · Advances in Clinical Medicine · doi:10.12677/acm.2022.1291173
Li, Y., Wang, J., Jing, X., Sun, Y., Tang, X., Guo, J., Zhang, Y., & Zhu, H. (2023) · Research Square · doi:10.21203/rs.3.rs-2468046/v1
Lu, Z., Li, S., Li, Y., & Zhang, X. (2023) · Research Square · doi:10.21203/rs.3.rs-2588738/v1
Rim, C. H. (2023) · Radiation Oncology Journal · doi:10.3857/roj.2023.01004
Yang, Y., Xiang, R., Fan, S., Xu, Y. K., Zhong, W., & Wang, M. (2026) · European journal of medical research · doi:10.2139/ssrn.4883996
Research Progress of Immune Checkpoint Inhibitors in Small Cell Lung Cancer
Han, H., Chen, Y., & Wang, X. (2024) · Science Discovery · doi:10.11648/j.sd.20241203.15
Pre-existing intratumoral stem-like CD8 + T-cells drive radiotherapy-induced tumor controlPreprint
Köksal, H., Herbst, M., Perreira, P., Nater, M., Regli, N., Boudjeniba, C., Borgoni, N. E., Cecconi, V., & van den Broek, M. F. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.10.16.618635
Toxicity When Combining Immunotherapy and Radiotherapy
Leaman-Alcibar, O., López‐Campos, F., Aller, J., Calín-Lorca, A., Zatarain‐Nicolás, E., Bande, M. F., & Navarro-Martín, A. (2025) · Springer eBooks · doi:10.1007/978-3-032-00775-9_339
Li, S. C., Zhuang, M., Lu, Z., Lv, X., Zhao, L., & Cui, J. (2025) · Research Square · doi:10.21203/rs.3.rs-7859919/v1
Zhang, X.-T., Ge, N., Xiang, Z.-J., & Liu, T. (2022) · Figshare · doi:10.6084/m9.figshare.21592463
Hu, Q., Zhou, C., Zhao, F., Song, X., Ding, Y., Wang, X., Wu, B., Wang, H., Chen, S., & Jia, B. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1731123
Xu, Y., Guan, H., Wu, Y., Huang, H., Yu, S., Yin, X., & Wang, M. (2026) · Journal of Translational Internal Medicine · doi:10.1515/jtim-2026-0044 · Cited by 1 · see citing works
Wang, L., Liu, Y., Zhao, W., Xing, L., Hui, Z., Liu, X., Chen, M., Wu, Y., Chen, L., Zhou, C., et al. (2026) · Cancer Letters · doi:10.1016/j.canlet.2026.218719
Self-citationWan, S., Hu, S., Yan, Y., Sun, F., Bian, D., Luo, J., Xie, D., He, W., Duan, L., Zhu, Y., et al. (2026) · MedComm · doi:10.1002/mco2.70972
Immunotherapy With Anti‐PD‐1 Versus Anti‐PD‐L1 in SCLC: A Comprehensive Retrospective Analysis
Yang, R., Gan, J., Yang, L., Chen, B., & Li, W. (2026) · MedComm · doi:10.1002/mco2.70872
Wen, Y., Cheng, N., Zhou, S., Zhu, H., & Ge, Q. (2026) · Frontiers in Genetics · doi:10.3389/fgene.2026.1927654
- Authors
- Welsh, J. W., Heymach, J. V., Guo, C., Menon, H., Klein, K., Cushman, T. R., Verma, V., Hess, K. R., Shroff, G., Tang, C., Skoulidis, F., Jeter, M., Comeaux, N., Patel, R. R., Chen, D., Ozgen, T., Nguyen, Q.-N., Chang, J. Y., Altan, M., Zhang, J., Papadimitrakopoulou, V. A., Simon, G. R., Byers, L. A., & Glisson, B.
- Affiliations
- The University of Texas MD Anderson Cancer Center (US)
- Ankara University (TR)
- Corresponding author
- Welsh, James W.
- ORCID
- Welsh, James W.
- Heymach, John V.
- Menon, Hari
- Cushman, Taylor R.
- Verma, Vivek
- Hess, Kenneth R.
- Shroff, Girish
- Tang, Chad
- Skoulidis, Ferdinandos
- Jeter, Melenda
- Comeaux, Nathan
- Patel, Roshal R.
- Chen, Dawei
- Ozgen, Tugce
- Nguyen, Quynh-Nhu
- Chang, Joe Y.
- Altan, Mehmet
- Zhang, Jianjun
- Papadimitrakopoulou, Vassiliki A.
- Simon, George R.
- Byers, Lauren A.
- Glisson, Bonnie
- Venue
- Journal of Thoracic Oncology
- Publisher
- Elsevier BV
- Published
- 2020-12
- Volume
- 15
- Issue
- 12
- Pages
- 1919-1927
- ISSN
- 1556-0864 (ISSN-L)
- PMC
- PMC10600713
- OpenAlex
- W3084355783
- Cited by
- 101
- References
- 31
- Citations by year
- 2026: 13 · 2025: 13 · 2024: 21 · 2023: 18 · 2022: 24 · 2021: 10 · 2020: 2
- FWCI
- 4.88
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Journal of Thoracic Oncology (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- AstraZeneca
- Sierra Oncology
- Genentech
- GlaxoSmithKline
- Johnson and Johnson
- Jazz Pharmaceuticals
- Eli Lilly and Company
- Jounce Therapeutics
- National Institutes of Health
- Spectrum Pharmaceuticals
- National Cancer Institute
- AbbVie
- Boehringer Ingelheim
- F. Hoffmann-La Roche
- Bristol-Myers Squibb
- Merck
- Novartis
- Topics
- Health Sciences › Medicine › Oncology › Lung Cancer Research Studies
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
- Health Sciences › Medicine › Otorhinolaryngology › Head and Neck Cancer Studies
- Keywords
- pembrolizumab, limited-stage small cell lung cancer, concurrent chemoradiotherapy, etoposide, platinum-based chemotherapy, prophylactic cranial irradiation, immune checkpoint inhibitors, pneumonitis, esophagitis, progression-free survival, overall survival, neuroendocrine tumors
- MeSH terms
- Adult, Antineoplastic Combined Chemotherapy Protocols, Cisplatin, Humans, Lung Neoplasms, Small Cell Lung Carcinoma, Chemoradiotherapy, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
